Unicycive Therapeutics (UNCY) Competitors $0.57 -0.03 (-5.00%) Closing price 04:00 PM EasternExtended Trading$0.57 +0.00 (+0.53%) As of 07:19 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesOwnershipSEC FilingsShort InterestTrendsBuy This Stock UNCY vs. RNAC, AURA, CGC, TSVT, ITOS, TERN, GLUE, LFCR, ALLO, and AVIRShould you be buying Unicycive Therapeutics stock or one of its competitors? The main competitors of Unicycive Therapeutics include Cartesian Therapeutics (RNAC), Aura Biosciences (AURA), Canopy Growth (CGC), 2seventy bio (TSVT), iTeos Therapeutics (ITOS), Terns Pharmaceuticals (TERN), Monte Rosa Therapeutics (GLUE), Lifecore Biomedical (LFCR), Allogene Therapeutics (ALLO), and Atea Pharmaceuticals (AVIR). These companies are all part of the "pharmaceutical products" industry. Unicycive Therapeutics vs. Cartesian Therapeutics Aura Biosciences Canopy Growth 2seventy bio iTeos Therapeutics Terns Pharmaceuticals Monte Rosa Therapeutics Lifecore Biomedical Allogene Therapeutics Atea Pharmaceuticals Unicycive Therapeutics (NASDAQ:UNCY) and Cartesian Therapeutics (NASDAQ:RNAC) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their media sentiment, valuation, profitability, dividends, analyst recommendations, risk, earnings, community ranking and institutional ownership. Is UNCY or RNAC more profitable? Unicycive Therapeutics has a net margin of 0.00% compared to Cartesian Therapeutics' net margin of -510.72%. Company Net Margins Return on Equity Return on Assets Unicycive TherapeuticsN/A N/A -29.88% Cartesian Therapeutics -510.72%N/A -6.03% Which has more volatility and risk, UNCY or RNAC? Unicycive Therapeutics has a beta of 2.14, indicating that its share price is 114% more volatile than the S&P 500. Comparatively, Cartesian Therapeutics has a beta of 0.51, indicating that its share price is 49% less volatile than the S&P 500. Do analysts prefer UNCY or RNAC? Unicycive Therapeutics currently has a consensus target price of $5.50, suggesting a potential upside of 870.02%. Cartesian Therapeutics has a consensus target price of $42.50, suggesting a potential upside of 349.50%. Given Unicycive Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe Unicycive Therapeutics is more favorable than Cartesian Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Unicycive Therapeutics 0 Sell rating(s) 0 Hold rating(s) 3 Buy rating(s) 1 Strong Buy rating(s) 3.25Cartesian Therapeutics 0 Sell rating(s) 2 Hold rating(s) 6 Buy rating(s) 0 Strong Buy rating(s) 2.75 Does the MarketBeat Community believe in UNCY or RNAC? Cartesian Therapeutics received 4 more outperform votes than Unicycive Therapeutics when rated by MarketBeat users. Likewise, 95.12% of users gave Cartesian Therapeutics an outperform vote while only 77.78% of users gave Unicycive Therapeutics an outperform vote. CompanyUnderperformOutperformUnicycive TherapeuticsOutperform Votes3577.78% Underperform Votes1022.22% Cartesian TherapeuticsOutperform Votes3995.12% Underperform Votes24.88% Do institutionals and insiders believe in UNCY or RNAC? 40.4% of Unicycive Therapeutics shares are owned by institutional investors. Comparatively, 86.9% of Cartesian Therapeutics shares are owned by institutional investors. 10.7% of Unicycive Therapeutics shares are owned by insiders. Comparatively, 57.9% of Cartesian Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth. Which has stronger valuation and earnings, UNCY or RNAC? Unicycive Therapeutics has higher earnings, but lower revenue than Cartesian Therapeutics. Unicycive Therapeutics is trading at a lower price-to-earnings ratio than Cartesian Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioUnicycive Therapeutics$680K100.58-$30.54M-$0.51-1.11Cartesian Therapeutics$34.17M7.18-$219.71M-$52.83-0.18 Does the media refer more to UNCY or RNAC? In the previous week, Cartesian Therapeutics had 1 more articles in the media than Unicycive Therapeutics. MarketBeat recorded 9 mentions for Cartesian Therapeutics and 8 mentions for Unicycive Therapeutics. Unicycive Therapeutics' average media sentiment score of 1.27 beat Cartesian Therapeutics' score of 0.33 indicating that Unicycive Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Unicycive Therapeutics 2 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Cartesian Therapeutics 2 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Neutral SummaryUnicycive Therapeutics and Cartesian Therapeutics tied by winning 9 of the 18 factors compared between the two stocks. Get Unicycive Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for UNCY and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart UNCY vs. The Competition Export to ExcelMetricUnicycive TherapeuticsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$68.76M$6.49B$5.36B$8.40BDividend YieldN/A2.66%5.22%4.11%P/E Ratio-0.598.9426.6219.74Price / Sales100.58251.31391.30117.36Price / CashN/A65.8538.2534.62Price / Book-5.156.456.804.51Net Income-$30.54M$143.98M$3.23B$248.18M7 Day Performance1.56%3.17%4.02%1.07%1 Month Performance-7.06%7.63%12.19%14.96%1 Year Performance-44.95%-2.38%17.04%6.70% Unicycive Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)UNCYUnicycive Therapeutics3.2501 of 5 stars$0.57-5.0%$5.50+864.9%-43.4%$68.76M$680,000.00-0.599News CoveragePositive NewsEarnings ReportAnalyst RevisionRNACCartesian Therapeutics1.557 of 5 stars$10.44+5.5%$42.50+307.1%-60.4%$270.78M$38.91M-0.2064News CoverageAnalyst RevisionGap UpAURAAura Biosciences2.4315 of 5 stars$5.35+2.3%$22.75+325.2%-16.5%$268.70MN/A-3.0950Earnings ReportInsider TradeGap UpCGCCanopy Growth1.4179 of 5 stars$1.46+11.5%$2.00+37.0%-82.5%$268.44M$276.75M-0.383,150TSVT2seventy bio1.5274 of 5 stars$5.00+0.2%$4.25-15.0%N/A$266.15M$37.86M-2.69440News CoveragePositive NewsITOSiTeos Therapeutics2.9935 of 5 stars$6.92+3.9%$25.50+268.5%-53.8%$264.86M$35M-2.2090Analyst RevisionGap UpHigh Trading VolumeTERNTerns Pharmaceuticals4.1164 of 5 stars$3.02-0.7%$18.38+508.4%-49.6%$263.76MN/A-2.5640News CoveragePositive NewsGap DownGLUEMonte Rosa Therapeutics2.1951 of 5 stars$4.27+4.4%$15.50+263.0%-16.0%$262.65M$75.62M-2.3390Positive NewsLFCRLifecore Biomedical1.2701 of 5 stars$6.98+0.1%$8.00+14.6%+11.7%$258.43M$130.31M-12.46690Analyst ForecastALLOAllogene Therapeutics3.4734 of 5 stars$1.17+0.9%$9.29+693.9%-55.2%$255.89M$22,000.00-0.75310Analyst RevisionAVIRAtea Pharmaceuticals2.4243 of 5 stars$2.96+8.8%$6.00+102.7%-19.4%$253.31MN/A-1.4370High Trading Volume Related Companies and Tools Related Companies Cartesian Therapeutics Alternatives Aura Biosciences Alternatives Canopy Growth Alternatives 2seventy bio Alternatives iTeos Therapeutics Alternatives Terns Pharmaceuticals Alternatives Monte Rosa Therapeutics Alternatives Lifecore Biomedical Alternatives Allogene Therapeutics Alternatives Atea Pharmaceuticals Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:UNCY) was last updated on 5/21/2025 by MarketBeat.com Staff From Our PartnersMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredGold Hits New Highs as Global Markets SpiralWhen Trump took office in 2017, gold was just $1,100 an ounce. By the time he left, it had soared to $1,839. ...Premier Gold Co | SponsoredWhite House to reset Social Security?Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon b...Altimetry | SponsoredThe Trump Dump is starting; Get out of stocks now?The first 365 days of the Trump presidency… Will be the best time to get rich in American history.Paradigm Press | SponsoredTrump’s treachery Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredBuffett’s favorite chart just hit 209% – here’s what that means for goldA Historic Gold Announcement Is About to Rock Wall Street For months, sharp-eyed analysts have watched the ...Golden Portfolio | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredIs President Trump Lying To You With This?President Trump’s economic transition isn’t without hardship. But what if there were a smart, tax-free way to ...Colonial Metals | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Unicycive Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Unicycive Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy UNCY Stock Free UNCY Stock Alerts